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Abstract
Purpose To provide an overview of treatment modalities for management of upper tract urothelial carcinoma (UTUC).
Methods In accordance with the standards for a scoping review, data presentation and discussion at the Consultation on 
UTUC in Stockholm, 6–7 September 2018, consensus was reached on the latest and most important treatment recommenda-
tions for UTUC. Using Pubmed, Web of Science, and Embase, publications were selected based on quality, clinical relevance, 
and level of evidence.
Results Kidney-sparing surgery should be attempted for low-grade UTUC. Radical nephroureterectomy with bladder cuff 
excision is first option for high-grade disease. Post-operative bladder instillation of chemotherapy should be offered after 
RNU to reduce intravesical recurrence rate. Identification of tumor grade and stage is crucial when selecting treatment. 
Ureteroscopic management of low-grade and non-invasive UTUC achieves disease-free survival similar to that offered by 
radical nephroureterectomy but seems to be a risk factor for intravesical recurrence. Lymphadenectomy appears important 
for high-risk disease, although the therapeutic benefit needs further validation. There is little evidence supporting use of 
Bacillus Calmette–Guérin (BCG) and mitomycin C as monotherapy and adjuvant treatment in UTUC. A randomized clini-
cal trial has indicated that platin-based chemotherapy for invasive UTUC improves disease-free survival, suggesting that 
adjuvant chemotherapy should be considered standard care for ≥ T2 N0–3M0 disease.
Conclusions Risk stratification assessment is feasible and mandatory in UTUC. Identification of tumor grade and stage is 
essential for optimal treatment selection. Kidney-sparing surgery should be offered in low-risk disease, whereas radical 
nephroureterectomy and adjuvant chemotherapy should be considered in high-risk disease.
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Introduction
The EAU guidelines for treatment of upper tract urothe-
lial carcinoma (UTUC) have evolved. RNU was the gold 
standard for all cases until 2013 but is recommended only 
for high-risk tumors since 2015 [1]. KSS is the preferred 
strategy for management of all low-risk UTUC in the 
2017–2018 edition. UTUC is relatively rare and due to the 
scarcity of prospective and randomized controlled studies 
(RCS), the evidence and grades of recommendations are 
limited regarding diagnostic and treatment procedures. 
The aim of Consultation on UTUC 2018 was to gather 
clinical and research experts in diagnostics and treatment 
of UTUC to discuss existing guidelines, and, by reviewing 
the literature, to add further recommendations. The experts 
were assigned different topics regarding UTUC. Due to the 
lack of RCSs, they were instructed to investigate the topic 
in accordance with a scoping review.
Treatment selection
The 2018 EAU guidelines recommend that endoscopic 
ablation be considered in low-risk cancers, whereas RNU 
is the first option in cases of organ-confined high-grade 
disease.
Tumor classification based on pathological grade and 
stage is a key point in treatment selection. Clinically, it is 
difficult to determine tumor stage in UTUC, and thus risk 
stratification of low- and high-risk tumors [1] is useful 
for identifying patients who are more suitable for KSS 
than for RNU. To define low-risk and high-risk UTUC, 
the cytological and histological grades of the tumor cells 
are the most essential factors [2, 3] although tumor size 
and multifocality also should be taken into consideration.
Grasso et al. [4] analyzed the outcome in 160 consecu-
tive patients undergoing either ureteroscopic treatment or 
extirpative RNU for UTUC. These investigators concluded 
that tumor grade was the most significant predictor of both 
overall survival (OS) and cancer-specific survival (CSS), 
regardless of treatment method. In a systematic review of 
the oncological outcomes of ureteroscopic or percutaneous 
treatment of UTUC [5], it was concluded that the rate of 
recurrence is high in endoscopically managed UTUC, and 
a grade-related risk of tumor progression and disease-spe-
cific mortality were also documented. The review further 
indicated that, for highly selected low-grade tumors, local 
endoscopic treatment might be comparable to RNU in 
terms of 5-year disease-specific survival (DSS). For high-
grade disease, DSS was poor, and endoscopic manage-
ment should only be considered for compelling imperative 
indications, including solitary kidney or severely impaired 
renal function.
Although there seems to be consensus regarding the 
importance of tumor grading, correct grading is challeng-
ing [6–8].
Kidney‑sparing surgery (KSS) for UTUC 
Focal treatment of UTUC includes endoscopic therapy: uret-
eroscopic or percutaneous; ureteral segmental resection; and 
local instillation of Bacillus Calmette–Guérin (BCG) vac-
cine or mitomycin C.
In patients with low-risk disease, survival rates after KSS 
are comparable with those after RNU, however, with lower 
morbidity and without kidney function loss [9]. The 2010 
United States Renal Data System (USRDS) Annual Data 
Report pointed out that 5-year overall survival for end-stage 
renal disease was only 39% and argued that KSS should 
also be considered for high-grade tumors after frank patient 
counseling in special, imperative cases [10].
Management of UTUC by ureteroscopy (URS)
In 2017, the International Consultation on Urologic Diseases 
(ICUD) reported an update on focal treatment of low-risk 
UTUC [11], stating that no prospective randomized stud-
ies were found to support surgical management guidelines. 
Twenty-one different series of ureteroscopic treatment 
(1989–2014) were reviewed, and the overall survival rates 
varied from 35 to 100% (median follow-up 14–32 months). 
In a cohort study of 15 patients who underwent endoscopic 
laser ablation as primary treatment for low-grade UTUC, the 
recurrence rate was 33% within a follow-up period of median 
25.5 months (range 13–51 months) [12]. The renal preser-
vation rate was 80%. A relatively high incidence of recur-
rences emphasizes the importance of stringent follow-up in 
patients treated endoscopically. In an assessment comparing 
the outcomes of endoscopic management of non-invasive 
T1 and RNU for UTUC [13], the DSS during 50 months 
of follow-up was equivalent for the two methods. However, 
RNU was significantly superior to endoscopy for T2 and T3 
tumors, with DSS of 91.7% vs 62.5% for T2 lesions, and 
progression-free survival (PFS) of 88.9% vs 55.6% for T3 
tumors.
In a retrospective study of 41 UTUC patients, Villa et al. 
[14] evaluated the cancer detection rate of a second-look 
URS performed within 60 days of the first URS with laser 
ablation. The cancer detection rate at second-look URS was 
51.2%, which emphasizes the necessity of a second look 
at 6–8 weeks and a stringent follow-up. In a meta-analysis 
examining the impact of URS before RNU on oncologi-
cal outcomes [15], patients with initial URS had a signifi-
cantly higher risk of bladder recurrence; however, that had 
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no impact on CSS, OS, recurrence-free survival (RFS), or 
metastasis-free survival (MFS). Several options are avail-
able for laser ablation, such as holmium, thulium, and neo-
dymium, but there is little evidence regarding the pros and 
cons of the different modalities [16].
Management of UTUC by percutaneous access
Percutaneous access can be an option in cases with difficult 
retrograde access, e.g. due to upper urinary tract anoma-
lies, urinary diversions or strictures. However, percutaneous 
access entails the risk of tumor seeding. The evidence base 
for percutaneous management is low, because evaluations in 
this area have entailed small case series with variability in 
duration of follow-up and measures of oncological outcome. 
A systematic review of percutaneous and ureteroscopic man-
agement of UTUC indicated that DSS in patients with T1 
tumors was similar for the two approaches (89% vs 91%) 
[5]; the 5-year DSS was 81–100% for low-grade disease and 
ranged from 69 to 86% for high-grade disease. The ICUD 
group reviewed ten different series of percutaneous access 
treatments for low-risk UTUC performed over the period 
1992–2015 [11], which showed CSS ranging from 75 to 
100% and kidney-preserving rates of 65–94%.
Management of UTUC by segmental ureteral 
resection
Segmental ureteral resection (SU) can be considered in 
selected patients with localized high-grade and inva-
sive UTUC, requiring kidney-sparing management due 
to impaired renal function or solitary kidney. With this 
approach, oncological outcomes equivalent to those 
observed after RNU have been observed [9]. Lymphadenec-
tomy is feasible during SU, but staging prior to surgery is 
of great importance [17]. A meta-analysis including 3963 
UTUC patients supported the equivalence between SU and 
RNU in terms of CSS, OS and RFS [18]. However, patients 
treated with SU were selected for favorable features and the 
rate of positive lymph node disease was significantly lower 
in this group. Patients receiving SU had significantly better 
renal function preservation and the authors suggested SU 
as first-line treatment in selected cases of high-risk disease.
Radical treatment of UTUC 
Indications
A tendency toward overtreatment was noted in a study of 
2244 patients who underwent RNU [19], showing that 25% 
of the patients had pT0, pTa, or pTis tumors, and 18% low-
grade tumors. RNU as first-line treatment for high-risk 
UTUC is challenged by the risk of chronic kidney disease. 
In a study of 336 UTUC patients, Lane et al. [20] determined 
the eligibility for cisplatin-based combination chemotherapy 
(CBCC) by measuring the estimated glomerular filtration 
rate (eGFR). The results showed that RNU eliminated CBCC 
as an adjuvant therapy option in 49% of high-risk patients, 
and only 22% of patients were eligible for post-RNU CBCC 
due to a decline in eGFR. The authors suggested that this 
problem might be resolved by applying multimodal treat-
ment paradigms, with a focus on neoadjuvant chemotherapy.
Radical nephroureterectomy (RNU) with bladder 
cuff excision
RNU with bladder cuff excision is the standard treatment 
for high-risk organ-confined UTUC, regardless of tumor 
location [1]. Due to the risk of tumor recurrence in the dis-
tal ureter and its orifice, the bladder cuff must be resected 
in connection with RNU. Several techniques are used for 
this purpose: endoscopic, transvesical, and extravesical 
approaches. A retrospective study evaluating recurrence 
and survival after laparoscopic nephroureterectomy (LNU) 
using either transvesical cystoscopic secured detachment and 
ligation or extravesical laparoscopic stapling found poorer 
RFS for patients treated with the latter method [21]. In a 
retrospective analysis of 2681 RNU-treated UTUC patients 
[22], endoscopic resection of bladder cuff, using transure-
thral resection with a hook-electrode, resulted in intravesical 
recurrence in a significantly larger number of patients than 
transvesical or extravesical approach. Hence, it was recom-
mended that this approach be avoided.
In a retrospective analysis of 324 UTUC patients treated 
with RNU, 1995–2008, open radical nephroureterectomy 
(ORN) was compared to LNU with regard to RFS and DSS 
[23]. Two-year RFS was found to be similar in the two 
groups: 38% and 42%, respectively. It should be noted that 
lymph node dissection (LND) was performed in 81% of the 
ORNs but in only 70% of the LNUs. The data from that 
retrospective evaluation were confirmed in a cohort study 
published in 2011 [24], which showed oncological equiva-
lence between ORN and LNU with regard to both RFS and 
CSS. Another investigation including 140 UTUC patients 
[25] reported that surgery duration was significantly longer 
for LNU than for ONU (240 vs 190 min.), but DSS did not 
differ significantly between the two methods. In a study of 
80 patients with non-metastatic UTUC [26], MFS and CSS 
were equivalent for LNU and ORN; however, when matching 
for T3 and high-grade tumors, CSS and MFS were statisti-
cally higher for ORN. Based on these results, ORN was sug-
gested as first-option treatment for patients with advanced 
stage disease. Retroperitoneal metastatic dissemination and 
metastases along the trocar pathway have been reported in 
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up to 2.8% after LNU [27], and hence precautions should 
be taken to avoid spillage during pneumoperitoneum [1].
Lymph node dissection in UTUC 
Evidence is limited regarding the therapeutic advantage of 
LND in UTUC. The optimal lymph node template and the 
exact oncological advantages of LND remain to be defined. 
Although an increased trend towards LND in RNU, 64% of 
1512 RNU-treated UTUC patients did not receive concomi-
tant LND [28]. Of patients treated laparoscopically, only 
24% had a lymph node dissection and had significantly fewer 
lymph nodes removed compared to patients treated by open 
RNU. Studies have indicated that LND involves a staging 
benefit by providing prognostic measures valuable for CSS. 
Roscigno et al. [29] concluded that nodal status was a sig-
nificant predictor of CSS, and that pNx was associated with 
a worse prognosis than pN0 for T2–T4 tumors: 5-year CSS 
rates were 35%, 69%, and 77% for N +, Nx, and N0 diseases, 
respectively. Kondo et al. [30] conducted a prospective non-
randomized study to compare the oncological outcomes of 
UTUC (pT2 or more) in 77 patients treated with both RNU 
and LND, and 89 treated with RNU only. CSS was signifi-
cantly higher in the group treated with both RNU and LND 
(89.8% vs 48%). This study also documented an important 
difference between renal pelvic and ureteral UTUC, in that 
patients with the latter disease did not benefit from LND in 
terms of CSS.
In 2007, Suttman et al. [31] published their conceptual 
evaluation of the fragility of LND as a therapeutic tool in 
urothelial cancer. This assessment highlighted the princi-
ples of stage migration in radical cystectomy with LND 
for urothelial muscle-invasive bladder cancer (MIBC), and 
the investigators questioned the therapeutic benefits of that 
approach. In a randomized prospective trial, Gschwend et al. 
[32] showed that extended removal of lymph nodes and radi-
cal cystectomy in invasive urinary bladder cancer did not 
reduce the rate of tumor recurrence in the expected range.
A translational study by Marits et al. [33] showed that 
tumor-draining nodes in urothelial cancer can be considered 
to be a part of the immunological defense against urothelial 
cancer. This was demonstrated as anti-tumor-specific T cells 
being upregulated in tumor-draining sentinel nodes but not 
in non-draining lymph nodes. Also, the phenomenon of a 
T-cell line of defense has recently been further examined in 
MIBC patients receiving neoadjuvant chemotherapy [34], 
and the results illustrate the potential importance of an intact 
set of active regional immunological defense cells.
Kondo et al. [35] showed that in pT3 or more advanced 
urothelial cancer, the extent of LND has a significant impact 
on CSS (all cases N0). In accordance with these findings, 
Roscigno et al. [36] observed longer survival in N0 patients, 
who had at least eight lymph nodes removed during RNU for 
UTUC, whereas neither RFS nor CSS was associated with 
the extent of LND in N + patients. In contrast, an additional 
investigation by Kondo et al. [37] showed that the particular 
template of LND, not the number of lymph nodes removed, 
influenced CSS in 80 UTUC patients with T2 or > N0, which 
suggests that the extent of LND should be determined by 
the template alone, not necessarily by the number of lymph 
nodes removed.
In summary, it seems that for patients with a high-grade 
tumor, a large tumor burden, and local invasion, LND is 
advantageous in terms of improving staging accuracy and 
can thereby serve as a counseling amendment in the individ-
ualized follow-up scheduling. It is also plausible that LND 
can be curative in a subpopulation with limited nodal dis-
ease, but such a therapeutic benefit remains to be evaluated. 
Moreover, it appears that the anatomic extent and complete-
ness of LND is an important aspect, although the chiefly 
retrospective data on the indications and accurate template 
for LND require further validation.
Instillation therapy with BCG and mitomycin C: 
monotherapy, adjuvant therapy, and the role 
of bladder instillation in UTUC management
Bladder instillation therapy
The risk of bladder recurrence after RNU for UTUC is 
22–47% but can be reduced by introducing intravesical 
chemotherapy (mitomycin C) [38, 39]. The beneficial effects 
of intravesical therapy have been documented in two rand-
omized clinical trials (RCTs) and a meta-analysis [38–40], 
showing that a single dose of mitomycin C administered 
within 72 h after RNU resulted in a 52% reduced risk of 
bladder tumor recurrence within the first post-operative year.
Instillation therapy in the upper urinary tract
Local recurrence rates as high as 70% have been observed 
in studies evaluating the efficacy of ureteroscopic treatment 
of UTUC [41]. A systematic review performed by Cutress 
et al. [5] found a 52% recurrence rate after endoscopic treat-
ment. Instillation of BCG vaccine or mitomycin C in the 
upper urinary tract via a percutaneous nephrostomy tube or 
a ureteral stent can be used as adjuvant therapy after KSS 
for Ta/T1 upper tract tumors or for treatment of carcinoma 
in situ [42, 43]. However, no RCTs have assessed such treat-
ment, and thus the level of evidence is low. A review evalu-
ating the outcomes of studies using topical adjuvant BCG for 
upper tract carcinoma in situ documented an initial positive 
response of 73%, a recurrence rate of 26%, and a progres-
sion rate of 14% [5]. The follow-up time varied from 20 
to 51 months. Complications reported included hematuria, 
2283World Journal of Urology (2019) 37:2279–2287 
1 3
pyrexia, fever, LUTS, septicemia (one fatal), and ureteral 
stricture.
Retrograde instillation via ureteral catheter
The most advantageous and reliable approach to access the 
urinary tract for instillation therapy has been discussed. Liu 
et al. [44] used a fluorescent dye solution to examine three 
different modes of delivery in a pig model. Compared with 
antegrade perfusion and vesico-ureteral reflux via a ureteral 
stent, applying retrograde infusion via an open-end ureteral 
catheter resulted in the highest staining intensity in all six 
pre-defined points in the urinary tract. Pollard et al. [45] 
had similar results in an ex vivo porcine model. Retrograde 
infusion through an open-ended ureteral catheter resulted 
in a stained surface area of 83.6% compared with areas of 
65.2% and 66.2% after delivery via an antegrade nephros-
tomy tube and reflux delivery through a JJ stent, respectively 
(p = 0.002). Clinical studies have not been conducted to con-
firm these experimental observations, and the clinical and 
pathophysiological consequences of high-volume infusion 
of chemotherapy have not been taken into consideration. 
High inflow pressure through the ureteral catheter might be 
necessary to reach all parts of the calyx system. Previous 
clinical studies of the pressure–flow relationship in the uri-
nary tract have indicated that very high non-physiological 
pressure levels may be reached [46, 47], which may result in 
adverse effects such as infections and systemic loading with 
the installation substances as a result of intrarenal and pye-
lovenous backflow. Retrograde instillation should be used 
with extreme caution due to the potential risk of ureteral 
obstruction and subsequent pyelovenous backflow. Moreo-
ver, the risks associated with increased intrarenal pressure 
(i.e., infection and urosepsis) should be taken into considera-
tion [46, 47].
Antegrade instillation via a nephrostomy tube
In a retrospective study including 64 renal units, antegrade 
BCG treatment was given with curative intent in 42 cases 
and with adjuvant intent in 22 cases [43]. During a mean 
follow-up of 42 months, local recurrence was observed in 
47% of cases. It seemed that better local disease control was 
achieved in patients treated with curative intent for Tis than 
in those treated adjuvantly for Ta/T1. In general, the treat-
ment was well tolerated, although adverse events, mostly 
minor (fever, lower urinary tract symptoms, hematuria, mild 
infection), occurred in 20% of patients. There was one case 
of fatal E. coli septicemia, which highlights the importance 
of maintaining low intrarenal pressure [46, 47].
Knoedler et al. [48] reviewed data from studies report-
ing upper urinary tract instillation therapy performed with 
curative intent in patients with Tis UTUC. The most widely 
used medical agent was BCG; approaches were antegrade 
or retrograde, or a combination of the two, and resulted in 
response rates of 60–80%. Metcalfe et al. [49] investigated 
the efficacy, safety, and tolerability of mitomycin C induction 
and maintenance adjuvant topical therapy in 27 endoscopi-
cally treated patients with primary Ta/T1 UTUC. During a 
median of 19 months of follow-up, 60% of the patients were 
recurrence free, 80% progression free, and 76% RNU free. 
The 3-year OS rate was 92.9%. A variety of complications 
were observed, including recurrent urinary tract infection, 
severe bladder spasms, ureteral stricture, and pyelonephritis.
Future options
Drug-eluting biodegradable stents and sustained-release 
mitomycin gel have been suggested as new treatment options 
for topical instillation therapy. The mitomycin gel functions 
as a liquid thermosensitive polymer at low temperatures 
but forms a gel at body temperature, resulting in prolonged 
retention and slow, sustained release of the therapeutic agent 
[50]. Barros et al. [51] developed a biodegradable stent that 
achieved 100% release of an impregnated anticancer drug 
in an artificial urine solution within 72 h. The development 
of such devices may have advantages in future treatment of 
UTUC.
Systemic therapies
Both similarities and differences are apparent when com-
paring bladder cancer and UTUC. Although there is con-
sistency between histological findings in the two diseases, 
the certainty of pre-operative staging and the availability 
of pre-operative histology are more complicated in UTUC. 
Platinum-based combination chemotherapy is expected to be 
effective in UTUC, but not all patients are eligible for such 
treatment due to comorbidity and impaired renal function 
after RNU.
Immune checkpoint inhibitors, which have favorable 
safety and anti-tumor activity profiles, have paved the way 
for a new era in the treatment of advanced UC. The primary 
molecular targets for these inhibitors are the programmed 
cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) 
checkpoints, which act as co-inhibitory signals that block 
anti-tumor effector T-cell responses [52]. Atezolizumab is a 
fully humanized monoclonal antibody of IgG1 isotype that 
selectively binds to PD-L1 and thereby enables T cells to 
overcome peripheral tolerance against tumor cells. In the 
IMvigor210 trial [53], atezolizumab showed durable activity 
and good tolerability in patients who had inoperable locally 
advanced or metastatic urothelial carcinoma that had pro-
gressed after previous platinum-based chemotherapy.
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To define prognostic relevance of the primary location of 
urothelial carcinoma with regard to survival of the patient, 
the European Organization for the Research and Treatment 
of Cancer (EORTC) conducted a retrospective analysis of 
prospectively collected data, from three investigations of 
urothelial carcinoma [54]. Patients were grouped by pri-
mary tumor location (bladder cancer [n = 878] vs UTUC 
[n = 161]). The bladder cancer patients had better perfor-
mance status. However, it was concluded that primary tumor 
location had no impact on PFS or OS in patients receiving 
platinum-based combination chemotherapy. The oncologi-
cal outcomes for metastatic disease were similar in the two 
groups.
Patients with advanced urothelial carcinoma progressing 
after platinum-based chemotherapy have a poor prognosis 
and limited treatment options. In a study of patients with 
platinum-refractory advanced urothelial carcinoma [55], 
treatment with the highly selective monoclonal antibody 
pembrolizumab was associated with longer OS (3 months) 
and a lower rate of adverse effects compared with chem-
otherapy as second-line treatment. The median OS was 
10.3 months for the total population of 542 patients.
Adjuvant chemotherapy
Only a few studies have focused on systemic chemotherapy 
in locally advanced UTUC. In a retrospective investigation 
of 43 UTUC patients with T2 or more advanced M0 dis-
ease, Kwak et al. [56] evaluated the effect of cisplatin-based 
chemotherapy following RNU. Thirty-two patients received 
chemotherapy, whereas 11 declined such treatment. After 
30 months of follow-up, the disease-free survival (DFS) was 
63.6% in the chemotherapy group compared to 37.5% in the 
surveillance group. Adjuvant chemotherapy was not associ-
ated with any survival benefit in 312 pT2-4N0/x patients 
treated for UTUC with RNU [57]. In this retrospective study, 
the most detrimental effects of chemotherapy were seen in 
patients with Nx or N0 disease. Such retrospective case 
series remain prone to selection bias and, thus, call for more 
randomized, prospective trials with clearly defined patient 
selection criteria.
The UK National Cancer Research Institute conducted 
a phase III randomized trial of peri-operative chemother-
apy vs surveillance in UTUC (designated the POUT trial) 
(NCT01993979). Eligible for inclusion were RNU-treated 
patients with pT2–pT4 N0M0 or pTany N1–N3M0 UTUC 
and a performance status of 0–1. Furthermore, GFR was 
to exceed 30 ml/min, and patients with significant comor-
bidity were excluded. The planned sample size was 383 
patients. The patients that were included were randomized 
to either surveillance or platinum-based chemotherapy 
within 90 days following RNU. In the chemotherapy group, 
all patients received gemcitabine, and either cisplatin or 
carboplatin. Carboplatin was permitted only if the GFR was 
30–49 ml/min. The primary endpoint of the POUT trial was 
DFS, and the secondary endpoints were MFS, OS, toxic-
ity, treatment compliance, and quality of life. Publication of 
the final results is eagerly awaited, but a provisional report 
has announced that the trial has met its primary endpoint 
demonstrating improved disease-free survival for patients 
who commence adjuvant chemotherapy within 90 days of 
nephroureterectomy (Birtle et al. Abstract 407; ASCO GU 
meeting, San Francisco, 2018).
Neoadjuvant chemotherapy
Neoadjuvant chemotherapy (NAC) for advanced UTUC is 
challenging due to the difficulties in pre-operative histologi-
cal staging. Limited retrospective data support neoadjuvant 
chemotherapy prior to RNU, but survival data must mature 
to yield valid information in this area [58]. A retrospective 
study of 234 patients with cT3–4 or cN + disease concluded 
that the 101 patients receiving neoadjuvant chemotherapy 
(cisplatin or carboplatin) had an improved RFS and CSS 
compared to the 133 patients that had no NAC. The overall 
survival was, however, not improved by NAC [59]. This is in 
opposite to findings by Porten et al. who reported improved 
OS and DSS for 31 patients with high-risk UTUC receiving 
cisplatin-based NAC [60]. Likewise, Hosogoe et al. reported 
improved oncological outcomes for 51 pair-matched patients 
(≥ T3 or N +) receiving cisplatin plus gemcitabine prior to 
RNU [61]. However, retrospective case series are highly 
prone to selection bias and non-randomized trials do not 
report true clinical benefit. To date, there are no randomized 
prospective trials of neoadjuvant systemic therapy in UTUC.
Conclusions
Identification of tumor grade and stage is essential for opti-
mal treatment of UTUC. RNU is the first option for patients 
with organ-confined high-grade disease, whereas KSS 
should be considered for those with non-invasive low-grade 
UTUC. Laparoscopic and open RNU are both acceptable 
techniques. However, in stage pT3 or more, open RNU is 
recommended. Post-RNU intravesical chemotherapy lowers 
bladder recurrence rates and should be mandatory. Instilla-
tion of BCG and mitomycin C as monotherapy in the upper 
urinary tract can be considered in selected patients, keeping 
in mind the limited evidence and the risk of complications. 
Seen the preliminary but promising results, adjuvant plati-
num-based chemotherapy should be considered for patients 
with T2 + disease after RNU.
In general, there is very little evidence regarding all treat-
ment modalities in UTUC. Further prospective randomized 
clinical trials are warranted in this area.
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